[1] Parkin DM,Bray F,Ferlay J,et al.Global Cancer Statistics, 2002.CA Cancer J Clin,2005,55:74-108. [2] Bode AM,Dong Z.Post-translational modification of p53 in tumorggenesis.Nat Rev Cancer,2004,4:793-805. [3] 陈复兴,刘军权,冯霞,等.一种体外扩增人γδT 细胞的新方法.细胞与分子免疫学杂志, 2007, 23: 662-664. [4] 向海艳,罗奇志,戴开金,等. 虎杖中白藜芦醇、白藜芦醇甙及大黄素的综合提取工艺.中国中药杂志,2000,25:651-653. [5] 张红雨,徐长庆,李鸿珠,等. 白藜芦醇对大鼠离体胸主动脉环的舒张作用.中国中药杂志,2015,30:1283-1286. [6] Solladié G, Yacine PJ, Maignan J. A reinvestigation of resveratrol synthesis by Perkins reaction. Application to the synthesis of aryl cinnamic acids. Tetrahedron, 2003, 59:3315-3321. [7] 丁刘刚,晏日安,黄雪松,等.功能性食品配料白藜芦醇的合成方法.现代食品科技,2007,23:83-85. [8] Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother, 2008, 57:1599-1609. [9] 李秀英, 夏良平, 赖延东, 等. PFP、GrB的共表达杀伤人喉癌Hep-2细胞的体外研究. 现代免疫学, 2008, 28:224-227. [10] Prakash MD, Bird CH, Bird PI.Active and zymogen forms of granzyme B are constitutively released from cytotoxic lymphocytes in the absence of target cell engagement. Immunol Cell Biol, 2009; 87:249-254. [11] Steinman L.Immune therapy for autoimmune diseases.Science,2004,305:212-216. [12] Blattman JN, Greenberg PD.Cancer immunotherapy:a treatment for the masses. Science,2004,305:200-205. [13] Miller J.Self-nonself discrimination by T lymphocyters.C R Biol,2004,327:399-408. [14] Feng YH,Zhou WL,Wu QL,et al.Low dose of resveratrol enhanced immune response of mice.Acta Pharmacol Sin,2002,23:893-897. [15] 黄俊,吴长有. CD107a/b 分子用于评价SARS-CoV/S抗原特异性免疫应答.免疫学杂志,2009,25:161-164. [16] Ebinu JO, Stang SL, Teixeira C, et al.RasGRP links T-cell receptor signaling to Ras. Blood, 2000,95:3199-3203. [17] Aktas E, Kucuksezer UC, Bilgic S, et al.Relationship between CD107a and cytotoxic activity. Cell Immunol, 2009, 254:149-154. [18] 周忠海, 陈复兴, 吕小婷,等. 人外周血γδT细胞CD107a的表达变化与细胞毒活性的关系.中国肿瘤生物治疗杂志, 2011, 18:301-305. |